icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
FstdfGYq32UHmqXL
Listen
